SEEL

Seeing Machines Limited (SEEL) | Rumor.io

Seeing Machines

SEEL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SEEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

Seelos Therapeutics, Inc. ($SEEL) is expected to perform well on SUI, with some users calling it an "alpha" opportunity.
There is anticipation for a significant event or release involving $SEEL, with some users speculating it will go live or take over on SUI.
Some users are expressing excitement and eagerness to invest in $SEEL, with phrases like "Let's go!" and "Who's ready to ape?" appearing in the posts.

Generated by AI

Sentiment

Of the messages about SEEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	66.67% +14.37
Bearish	—	—	—	33.33% -14.37

Bullish· Sep 27

$SEEL has a low float of 430K, which could lead to significant price movements.
The upcoming reverse stock split could be a catalyst for the stock to reach the moon, especially with the right additional news.
$SEEL's low float and recent price movements are comparable to those of $ONCO, which recently experienced a significant price increase following a reverse stock split.

Bearish· Sep 27

$SEEL has experienced significant price drops, down 20% on the recent RS and 99.43% in a year.
The company's management has been criticized for its performance, with some calling for the CEO to be fired and others questioning how the company remains in business.
The stock has undergone multiple reverse splits, reducing its market cap from $150mm to less than $2mm, and some investors have lost significant amounts of money due to these actions.

Generated by AI

Topics

Of the messages about SEEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Sep 27

Roth Capital analyst Jonathan Aschoff upgraded Seelos Therapeutics (SEEL) from Neutral to Buy with a price target of $8.00 (from $2.50).
The upgrade was based on reconsidering the Part A results for the SLS-002 trial and the current stock price, with the SLS-005 trial added to the Phase 2/3 HEALEY ALS trial seen as upside.
Seelos Therapeutics shares traded higher after the upgrade, with the stock price increasing by over 18% on the news.

Announcements· Sep 27

Seelos Therapeutics, Inc. ($SEEL) has announced a 1-for-16 reverse stock split, reducing the share float to approximately 431,000 from 6.9 million.
The reverse stock split will also reduce the number of shares outstanding from 6.9 million to 431,000.
The company's shares outstanding were previously 6.9 million, but will be reduced to 431,000 after the 1-for-16 reverse stock split.

Technical Analysis· Sep 24

Seelos Therapeutics, Inc. ($SEEL) is waiting for a clear 0.54 breakout to potentially reach 0.7.
The stock's trend line is still positive, and it needs to hold 0.50 to consolidate and draw in fresh buyers.
$SEEL is attempting to break out of a wedge and has high volume, with some analysts expecting it to "Booooom" if it succeeds.

Generated by AI

Community

Of the messages about SEEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	49.33%
Newcomers	—	—	—	50.67%

Regulars· Sep 27

SEEL's regulars discuss the recent $15M private placement memorandum agreement with Spark Market, a significant development for the company's capital structure.
The regulars are focused on the potential implications of this deal on SEEL's financials and its ability to fund its operations and growth plans.
There is ongoing debate among SEEL's regulars about the strategic significance of this agreement and how it may impact the company's future prospects.

Newcomers· Sep 27

Newcomers to the Seelos Therapeutics, Inc. (SEEL) market are noting the 1-for-16 reverse stock split, which has significantly reduced the share float from 6.9M to around 431K.
Investors are discussing the impact of the reverse split on SEEL's share price and market capitalization, as well as the potential for increased volatility.
Some newcomers are criticizing the decision to hand out fractional shares post-split, and the lack of information provided to investors about the split.

Generated by AI

Also Discussed

Investors talking about SEEL also mention

#	Name	Attention
1	Bio-Path Holdings Inc.BPTH	0%0
2	Akari Therapeutics Plc ADRAKTX	0%0
3	Precipio Inc.PRPO	0%0
4	NM - Navios Maritime Holdings Inc.	——
5	ONCT - Oncternal Therapeutics, Inc.	——
6	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
7	OBLN - Obalon Therapeutics, Inc.	——
8	Immunic, Inc.IMUX	0%0
9	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
10	Cardiff Oncology Inc.CRDF	0%+0

Seeing Machines Limited

Technology
Software - Infrastructure

Seeing Machines Limited is an advanced computer vision technology company specializing in driver and occupant monitoring systems to enhance transport safety. The company develops, sells, and licenses AI-powered products that detect and manage driver fatigue, distraction, and impairment in real-time, using human data-driven algorithms, embedded processing, and optics to analyze head pose, eye gaze, and eyelid movements under challenging conditions. Operating through OEM and Aftermarket segments, it serves automotive, aviation, mining, transport, fleet, and off-road industries via partnerships with Tier 1 suppliers and direct customers. Notable innovations include Guardian solutions for retrofitting commercial vehicles, 3D Cabin Perception Mapping, and collaborations like those with Mitsubishi Electric and Airy3D for next-generation in-cabin sensing. Headquartered in Canberra, Australia, with a global presence across Europe, North America, Asia-Pacific, and beyond, Seeing Machines employs around 393 people and contributes to regulatory advancements, such as UK mandates for distraction warnings and Australia's NHVR fatigue management codes, aiming to reduce the 1.35 million annual transport fatalities worldwide.

Website

Location

80 Mildura Street

Fyshwick, ACT, 2609

Australia

Social

What share of all stock conversation is about SEEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

Seelos Therapeutics, Inc. ($SEEL) is expected to perform well on SUI, with some users calling it an "alpha" opportunity.
There is anticipation for a significant event or release involving $SEEL, with some users speculating it will go live or take over on SUI.
Some users are expressing excitement and eagerness to invest in $SEEL, with phrases like "Let's go!" and "Who's ready to ape?" appearing in the posts.

Generated by AI

Sentiment

Of the messages about SEEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	66.67% +14.37
Bearish	—	—	—	33.33% -14.37

Bullish· Sep 27

$SEEL has a low float of 430K, which could lead to significant price movements.
The upcoming reverse stock split could be a catalyst for the stock to reach the moon, especially with the right additional news.
$SEEL's low float and recent price movements are comparable to those of $ONCO, which recently experienced a significant price increase following a reverse stock split.

Bearish· Sep 27

$SEEL has experienced significant price drops, down 20% on the recent RS and 99.43% in a year.
The company's management has been criticized for its performance, with some calling for the CEO to be fired and others questioning how the company remains in business.
The stock has undergone multiple reverse splits, reducing its market cap from $150mm to less than $2mm, and some investors have lost significant amounts of money due to these actions.

Generated by AI

Topics

Of the messages about SEEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Sep 27

Roth Capital analyst Jonathan Aschoff upgraded Seelos Therapeutics (SEEL) from Neutral to Buy with a price target of $8.00 (from $2.50).
The upgrade was based on reconsidering the Part A results for the SLS-002 trial and the current stock price, with the SLS-005 trial added to the Phase 2/3 HEALEY ALS trial seen as upside.
Seelos Therapeutics shares traded higher after the upgrade, with the stock price increasing by over 18% on the news.

Announcements· Sep 27

Seelos Therapeutics, Inc. ($SEEL) has announced a 1-for-16 reverse stock split, reducing the share float to approximately 431,000 from 6.9 million.
The reverse stock split will also reduce the number of shares outstanding from 6.9 million to 431,000.
The company's shares outstanding were previously 6.9 million, but will be reduced to 431,000 after the 1-for-16 reverse stock split.

Technical Analysis· Sep 24

Seelos Therapeutics, Inc. ($SEEL) is waiting for a clear 0.54 breakout to potentially reach 0.7.
The stock's trend line is still positive, and it needs to hold 0.50 to consolidate and draw in fresh buyers.
$SEEL is attempting to break out of a wedge and has high volume, with some analysts expecting it to "Booooom" if it succeeds.

Generated by AI

Community

Of the messages about SEEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	49.33%
Newcomers	—	—	—	50.67%

Regulars· Sep 27

SEEL's regulars discuss the recent $15M private placement memorandum agreement with Spark Market, a significant development for the company's capital structure.
The regulars are focused on the potential implications of this deal on SEEL's financials and its ability to fund its operations and growth plans.
There is ongoing debate among SEEL's regulars about the strategic significance of this agreement and how it may impact the company's future prospects.

Newcomers· Sep 27

Newcomers to the Seelos Therapeutics, Inc. (SEEL) market are noting the 1-for-16 reverse stock split, which has significantly reduced the share float from 6.9M to around 431K.
Investors are discussing the impact of the reverse split on SEEL's share price and market capitalization, as well as the potential for increased volatility.
Some newcomers are criticizing the decision to hand out fractional shares post-split, and the lack of information provided to investors about the split.

Generated by AI

Seeing Machines

Social

May 27

Sentiment

Bullish· Sep 27

Bearish· Sep 27

Topics

Analysts· Sep 27

Announcements· Sep 27

Technical Analysis· Sep 24

Community

Regulars· Sep 27

Newcomers· Sep 27

Also Discussed

Seeing Machines Limited

Company Information

Location

Also Discussed

Social

May 27

Sentiment

Bullish· Sep 27

Bearish· Sep 27

Topics

Analysts· Sep 27

Announcements· Sep 27

Technical Analysis· Sep 24

Community

Regulars· Sep 27

Newcomers· Sep 27